Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
Jacobs Center for Productive Youth Development, University of Zurich, Zurich, Switzerland.
Eur Addict Res. 2022;28(3):186-198. doi: 10.1159/000520178. Epub 2021 Dec 3.
Debates about the legalization of illegal substances (e.g., cannabis) continue around the globe. A key consideration in these debates is the adequate protection of young people, which could be informed by current prevalence and age-of-onset patterns. For Switzerland, such information is limited, which is particularly true for women, despite advanced political efforts to legalize cannabis. The objective of the current study was to investigate substance use prevalence rates and ages of onset in a community-representative sample of female and male young adults in Switzerland.
Data came from the Zurich Project on the Social Development from Childhood to Adulthood (z-proso). In 2018, participants (N = 1,180, 50.8% females) were ∼20 years old. Lifetime and past-year use of alcohol, tobacco, cannabinoids, stimulants, hallucinogens, opioids, and benzodiazepines were assessed with an extensive substance use questionnaire. Additionally, ages of onsets of the respective substances were estimated by averaging participants' self-reported ages of onsets from ages 13 to 20 (max. 4 assessments).
57% of 20-year-olds had used cannabinoids, 16% stimulants, 15% opioids (mostly codeine), and 8% hallucinogens in the past year. Males had higher prevalence than females for most drugs; nevertheless, females' prevalence rates were notably high. Legal substance use was typically initiated 1.3-2.7 years before legal selling age. Thus, almost half of the sample had consumed alcohol and tobacco by age 14. More than 40% of the total sample had smoked cannabis by age 16. Males initiated use of legal substances and cannabis earlier than females.
Our recent community-representative data suggested unexpectedly high levels and early onsets of substance use compared to a previous Swiss surveys and also the European average. Drug policy debates should consider urban substance use patterns when considering legalization efforts.
关于非法物质(例如大麻)合法化的辩论在全球范围内持续进行。这些辩论的一个关键考虑因素是对年轻人的充分保护,这可以通过当前的流行程度和发病年龄模式来提供信息。对于瑞士来说,这种信息是有限的,特别是对于女性,尽管在大麻合法化方面做出了先进的政治努力。本研究的目的是在瑞士具有代表性的社区青年男女样本中调查物质使用流行率和发病年龄。
数据来自苏黎世儿童到成年期社会发展项目(z-proso)。在 2018 年,参与者(N=1180,50.8%为女性)年龄约为 20 岁。使用广泛的物质使用问卷评估了参与者一生中以及过去一年中使用酒精、烟草、大麻、兴奋剂、迷幻剂、阿片类药物和苯二氮䓬类药物的情况。此外,通过平均参与者从 13 岁到 20 岁(最多 4 次评估)报告的发病年龄来估计各自物质的发病年龄。
20 岁的人中,57%过去一年中使用过大麻,16%使用过兴奋剂,15%(主要是可待因)使用过阿片类药物,8%使用过迷幻剂。大多数药物中,男性的使用率高于女性;然而,女性的使用率相当高。合法物质的使用通常在合法销售年龄之前 1.3-2.7 年开始。因此,几乎一半的样本在 14 岁时就已经饮酒和吸烟了。超过 40%的总样本在 16 岁时就已经吸食大麻。男性比女性更早开始使用合法物质和大麻。
与之前的瑞士调查和欧洲平均水平相比,我们最近的社区代表性数据显示,物质使用水平和发病年龄出人意料地高。在考虑合法化努力时,毒品政策辩论应该考虑城市物质使用模式。